LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces it is investigating claims against CTI BioPharma Corp. (“CTI” or the “Company”) (Nasdaq: CTIC) concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by CTI were false and misleading and/or failed to disclose material information regarding the Company’s financial performance.
The investigation will focus on whether the Company failed to disclose that: (1) CTI’s clinical trials showed that patient deaths were related to pacritinib usage; (2) CTI’s application for the approval of pacritinib would likely be withdrawn; (3) the Company’s future revenues were impaired; and (4) that the company lacked adequate internal controls.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.